Skip to main content
. Author manuscript; available in PMC: 2014 Dec 10.
Published in final edited form as: J Control Release. 2013 Apr 30;172(2):10.1016/j.jconrel.2013.04.016. doi: 10.1016/j.jconrel.2013.04.016

Figure 1.

Figure 1

Microneedles coated with inactivated virus and DNA influenza vaccines. (A) Representative array of five microneedles coated with fluorescein-conjugate BSA shown by bright-field microscopy (scale bar = 800 µm). The coating solution contained 6 mg/ml placebo DNA (B, D, F, H) Fluorescence and (C, E, G, I) bright-field microscopy images of individual microneedles coated with fluorescein-conjugate BSA coated using a coating solution containing (B, C) 2 mg/ml (D, E) 4 mg/ml (F, G) 6 mg/ml (H, I) 8 mg/ml placebo DNA (scale bar = 150 µm).